Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including kickbacks, billing fraud, ...
TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...
Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...
Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...
If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a ...
Scorpion Capital accuses TransMedics of fraudulent practices, kickbacks, and racketeering, setting a price target of $0.00. TransMedics denies the claims, stating the allegations aim to manipulate ...
Shares of organ transplant innovator TransMedics Group ( TMDX -1.41%) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence. TransMedics was the target of an ...
We maintain cautious stance on TransMedics investment due to high-risk factors. Read here for an analysis of TMDX stock drop and future prospects.
Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan ...
Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback